This company has been marked as potentially delisted and may not be actively trading. VIVUS (VVUS) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock VVUS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin LymphomaApril 14, 2025 | globenewswire.comVIVUS' QSYMIA® to be Featured on Health Uncensored with Dr. DrewMarch 19, 2025 | globenewswire.comVIVUS Launches QSYMIA® in the United Arab EmiratesMarch 10, 2025 | globenewswire.comVIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight ManagementMarch 4, 2025 | globenewswire.comVIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025January 13, 2025 | globenewswire.comVIVUS Shares Significant Regulatory Update on QSYMIA®October 28, 2024 | globenewswire.comVIVUS Announces Label Update for QSYMIA®October 23, 2024 | tmcnet.comVIVUS Provides Update on Pipeline and Program MilestonesJanuary 8, 2024 | markets.businessinsider.comMetaview announces Answers, the world's first conversational AI for the interview processMay 25, 2023 | it.tmcnet.comWhy aren’t new drugs that can help you lose weight more widely used? - MarketWatchOctober 2, 2022 | marketwatch.com'There's no way that patients are going to be able to afford that.' Why aren't new drugs that can help you lose weight more widely used? - MorningstarOctober 2, 2022 | morningstar.comMErectile Dysfunction Drugs Market to Surpass Around USD 4079.9 Million by 2028, Says Brandessence Market Research - Yahoo FinanceSeptember 23, 2022 | finance.yahoo.comForm DEF 14A Catalent, Inc. For: Oct 27 - StreetInsider.comSeptember 16, 2022 | streetinsider.comObesity Management Market Expanding at an Impressive CAGR - GlobeNewswireSeptember 9, 2022 | globenewswire.comGlobal Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - Yahoo FinanceAugust 26, 2022 | finance.yahoo.comGlobal Human Reproductive Technology Products and Markets Analysis Report 2022: Data from 2020-2021, Estimates for 2022, and CAGR Projections through 2027 - PR NewswireAugust 26, 2022 | prnewswire.com2022-08-15 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - StockhouseAugust 17, 2022 | stockhouse.comPetros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 - StreetInsider.comAugust 15, 2022 | streetinsider.comKaléo Announces Executive Appointments and New Government Business Unit - Yahoo FinanceAugust 11, 2022 | finance.yahoo.comIcahn Enterprises L P : Reports Second Quarter 2022 Financial Results - Form 8-K - Marketscreener.comAugust 5, 2022 | marketscreener.comMGlobal Cystic Fibrosis Market Report 2022-2030: CFTR Modulators Segment to Dominate the Market - BenzingaAugust 2, 2022 | benzinga.comGlobal Cystic Fibrosis Market Report 2022: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts 2020-2030 - ResearchAndMarkets.com - Business WireJuly 31, 2022 | businesswire.comGlobal Achondroplasia Market to Surpass US$ 1100.97 Million by 2030, Says Coherent Market Insights (CMI) - GlobeNewswireJuly 26, 2022 | globenewswire.comThe best stock investing strategy for 2022: Don’t buy the dip, buy the dividend - FortuneJuly 14, 2022 | fortune.comBioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - Yahoo FinanceJuly 5, 2022 | finance.yahoo.comBioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - StreetInsider.comJuly 5, 2022 | streetinsider.comOverweight Treatment Market estimated to surge ahead at a CAGR of 7.9% by the end of 2032 - Persistence M - BenzingaJune 8, 2022 | benzinga.com2022-05-16 | NDAQ:PTPI | Press Release | Petros Pharmaceuticals Inc. - StockhouseMay 16, 2022 | stockhouse.com Get VIVUS News Delivered to You Automatically Sign up to receive the latest news and ratings for VVUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VVUS Media Mentions By Week VVUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VVUS News Sentiment▼0.001.03▲Average Medical News Sentiment VVUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VVUS Articles This Week▼00▲VVUS Articles Average Week Get the Latest News and Ratings for VVUS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for VIVUS and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Eli Lilly and Company News Today Johnson & Johnson News Today AbbVie News Today Merck & Co., Inc. News Today Pfizer News Today Bristol Myers Squibb News Today Zoetis News Today Royalty Pharma News Today Jazz Pharmaceuticals News Today Corcept Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VVUS) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VIVUS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VIVUS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access